These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 24285872)

  • 1. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma.
    Hakimi AA; Furberg H; Zabor EC; Jacobsen A; Schultz N; Ciriello G; Mikklineni N; Fiegoli B; Kim PH; Voss MH; Shen H; Laird PW; Sander C; Reuter VE; Motzer RJ; Hsieh JJ; Russo P
    J Natl Cancer Inst; 2013 Dec; 105(24):1862-70. PubMed ID: 24285872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
    Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
    Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.
    Hakimi AA; Ostrovnaya I; Jacobsen A; Susztak K; Coleman JA; Russo P; Winer AG; Mano R; Sankin AI; Motzer RJ; Voss MH; Offit K; Purdue M; Pomerantz M; Freedman M; Choueiri TK; Hsieh JJ; Klein RJ
    Cancer; 2016 Feb; 122(3):402-10. PubMed ID: 26505625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of body mass index in Korean patients with renal cell carcinoma.
    Jeon HG; Jeong IG; Lee JH; Lee CJ; Kwak C; Kim HH; Lee SE; Lee E
    J Urol; 2010 Feb; 183(2):448-54. PubMed ID: 20006879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.
    Mendoza-Pérez J; Gu J; Herrera LA; Tannir NM; Zhang S; Matin S; Karam JA; Wood CG; Wu X
    Cancer; 2017 Sep; 123(18):3617-3627. PubMed ID: 28543182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
    Manley BJ; Zabor EC; Casuscelli J; Tennenbaum DM; Redzematovic A; Becerra MF; Benfante N; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Ogawa S; Arcila ME; Voss MH; Feldman DR; Coleman JA; Reuter VE; Motzer RJ; Russo P; Hsieh JJ; Hakimi AA
    Eur Urol Focus; 2017 Oct; 3(4-5):421-427. PubMed ID: 28753773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression.
    Marcon J; DiNatale RG; Sanchez A; Kotecha RR; Gupta S; Kuo F; Makarov V; Sandhu A; Mano R; Silagy AW; Blum KA; Nassau DE; Benfante NE; Ortiz MV; Carlo MI; Chan TA; Motzer RJ; Voss MH; Coleman J; Russo P; Reuter V; Hakimi AA; Reznik E
    Clin Cancer Res; 2020 Jul; 26(14):3629-3640. PubMed ID: 32220885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling the BMI paradox in different renal cortical tumors: insights from the INMARC registry.
    Saitta C; Afari JA; Walia A; Patil D; Tanaka H; Hakimi K; Wang L; Meagher MF; Liu F; Nguyen MV; Puri D; Cerrato C; Saidian A; Kobayashi M; Fukuda S; Fujii Y; Master V; Derweesh IH
    Urol Oncol; 2024 Apr; 42(4):119.e1-119.e16. PubMed ID: 38341362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma.
    Parker AS; Lohse CM; Cheville JC; Thiel DD; Leibovich BC; Blute ML
    Urology; 2006 Oct; 68(4):741-6. PubMed ID: 17070345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors.
    Kamat AM; Shock RP; Naya Y; Rosser CJ; Slaton JW; Pisters LL
    Urology; 2004 Jan; 63(1):46-50. PubMed ID: 14751346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and prognostic significance of fatty acid synthase in clear cell renal cell carcinoma.
    Yuan Y; Yang X; Li Y; Liu Q; Wu F; Qu H; Gao H; Ge J; Xu Y; Wang H; Wang Y; Zhao Z
    Pathol Res Pract; 2020 Nov; 216(11):153227. PubMed ID: 33027752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
    Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
    Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and prognostic value of potential dependency genes in clear cell renal cell carcinoma based on a large-scale CRISPR-Cas9 and RNAi screening database DepMap.
    Shi B; Ding J; Qi J; Gu Z
    Int J Med Sci; 2021; 18(9):2063-2075. PubMed ID: 33850477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.
    Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC
    Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma.
    Donin NM; Pantuck A; Klöpfer P; Bevan P; Fall B; Said J; Belldegrun AS; Chamie K
    Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1326-32. PubMed ID: 27418270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis.
    Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Mistretta FA; Tian Z; Musi G; Montanari E; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
    Urol Oncol; 2020 May; 38(5):506-514. PubMed ID: 32139292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
    Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM
    Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.
    Fu Q; Liu Z; Pan D; Zhang W; Xu L; Zhu Y; Liu H; Xu J
    Cancer Sci; 2014 Nov; 105(11):1427-34. PubMed ID: 25155155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.